Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial

Yuh-Chin Huang   ¹ , MD ;   Peter Morris   ² , MD ;   Robert Owens   ³ , MD ;   Carlos Guardia   ⁴ , MD ;   Steven Keller   ⁵ , MD ;   Waldo Belloso   ⁶ , MD ;   Lawrence Weinstein   ⁴ , MIE, MBA ;   Phillip Simmons   ⁴ , MS ;   Steven Simonson   ⁴ , MD

¹ Duke University Medical Center, Durham, NC, United States

² Department of Medicine, University of Alabama, Birmingham, AL, United States

³ Department of Medicine, University of California, San Diego, La Jolla, CA, United States

⁴ Windtree Therapeutics (United States), Warrington, PA, United States

⁵ Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States

⁶ Department of Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina